Protara Therapeutics, Inc. — Director's Dealing 2017

Jun 30, 2017

SEC Form 4/A — Form 4/A

Issuer: PROTEON THERAPEUTICS INC (PRTO)
CIK: 0001359931
Period of Report: 2017-06-22

Reporting Person: TVM Life Science Ventures VI GmbH & Co KG (Director, 10% Owner)
Reporting Person: TVM Life Science Ventures VI LP (Director, 10% Owner)
Reporting Person: Birner Hubert (Director, 10% Owner)
Reporting Person: Fischer Stefan (10% Owner)
Reporting Person: SCHUHSLER HELMUT (10% Owner)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-06-22	Series A Convertible Preferred Stock	$.9949	P	372	Acquired		Common Stock, $0.001 par value (373907)	Direct

Footnotes

F1: This amendment to the original Form 4 does not amend any item originally reported in Table II and the first line item of Table II is restated in this amendment for the sole purpose of gaining access to the electronic filing system; footnotes relating to such first line item are included for completeness and have not been amended. This amendment is made by the Reporting Persons solely to include the power of attorney attached hereto as Exhibit 24.

F2: The shares are directly held by TVM Life Science Ventures VI GMBH & Co. KG ("TVM VI"). Hubert Birner ("Birner"), Stefan Fischer ("Fischer"), and Helmut Schuhsler ("Schuhsler") are members of the investment committee of TVM Life Science Management VI L.P. ("TVM VI Management"), a special limited partner of TVM VI, with voting and dispositive power over the shares held by TVM VI. TVM VI Management, Birner, Schuhsler and Fischer each disclaim beneficial ownership of the shares held by TVM VI, except to the extent of any pecuniary interest therein, if any. Birner is a director of the issuer.

F3: The Series A convertible preferred stock (the "Series A Stock") is convertible, at the option of the holder, into Proteon Therapeutics Inc. common stock, $0.01 par value per share (the "Common Stock"), at a price per share equal to $0.9949.

F4: The Series A Stock has no expiration date.

F5: The certificate of designations for the Series A Stock contains a provision prohibiting conversion to the extent that upon conversion the holder, together with its affiliates and any "group" members, would beneficially own in excess of 9.985% of the number of shares of Common Stock then outstanding.